FDA Commissioner Warns Against "Illegal Copycat" Weight-Loss Drugs
FDA takes aim at compounded weight-loss drugs like Hims' $49 Wegovy alternative, raising safety concerns over unapproved copycat medications flooding the market.
NOTRELOAD AI
Doximity Stock Plunges 30% on Weak Guidance and CFO Medical Leave
Doximity (DOCS) shares tumbled in premarket trading after the healthcare platform cut its revenue forecast and announced its CFO's temporary medical leave.
Molina Healthcare Plunges on Weak 2026 Profit Outlook
Molina Healthcare shares drop 29% after forecasting 2026 earnings at $5/share vs. Wall Street's $13.71 estimate, while exiting Medicare Part D amid rising medical costs.
Goldman Sachs Starts Coverage on Biohaven with Buy Rating
Goldman Sachs initiates coverage on Biohaven with a Buy rating and $23 price target, highlighting BHV-1400 and its potential in the large IgA nephropathy market.
Coty Withdraws Guidance as New CEO Launches "Curated" Turnaround Strategy
CoverGirl owner Coty scraps 2026 outlook and unveils strategic reset under new CEO Markus Strobel. Shares fall 10% as company refocuses on core prestige brands.
Bloom Energy Crushes Q4 Earnings as AI Power Demand Surges – 2026 Outlook Soars
Bloom Energy (BE) reports strong Q4 2025 results with 36% revenue growth driven by AI data centers. Company forecasts $3.1-3.3B revenue for 2026, beating Wall Street expectations.